These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33598878)

  • 1. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Wang Y; Singh K; Dizon D; Graves T; Amin A; Yakirevich E
    Breast Cancer Res Treat; 2021 Apr; 186(3):667-676. PubMed ID: 33598878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
    Lien HC; Lo C; Lee YH; Lin PH; Wang MY; Kuo WH; Tsai LW; Lu YS; Hu HW; Li YC; Huang CS
    Breast Cancer Res; 2024 Jun; 26(1):100. PubMed ID: 38867307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study.
    Jiao D; Li G; Dai H; Wang J; Zhang J; Hou Y; Guo X; Zhao Y; Gong X; Liu Z
    Oncologist; 2024 Jul; 29(7):e877-e886. PubMed ID: 38537665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
    BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
    Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
    Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
    Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
    Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
    Rakha EA; Miligy IM; Quinn CM; Provenzano E; Shaaban AM; Marchiò C; Toss MS; Gallagy G; Murray C; Walshe J; Katayama A; Eldib K; Badr N; Tanchel B; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Ellis IO; Lee AHS
    Br J Cancer; 2021 May; 124(11):1836-1842. PubMed ID: 33762723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
    Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
    Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
    Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
    Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
    Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
    Yi X; Hu S; Ma M; Huang D; Zhang Y
    Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
    Ajabnoor R; Zhang G; Hu Y; Gao Y; Finkelman BS; Turner BM; Yi S; Dhakal A; Audeh W; Li Z; Li X; Hicks DG; Zhang H
    Mod Pathol; 2024 Aug; 37(8):100530. PubMed ID: 38810729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
    Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
    Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
    Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
    Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy.
    Chiu YN; Hsu CY; Lien PJ; Chao TC; Liu CY; Lin YS; Wang YL; Tsai YF; Tseng LM
    J Chin Med Assoc; 2023 Apr; 86(4):409-417. PubMed ID: 36689250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
    Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
    BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.